Neoleukin Therapeutics (NASDAQ:NLTX) shares saw strong trading volume on Monday . 2,175,578 shares traded hands during mid-day trading, an increase of 1,832% from the previous session’s volume of 112,612 shares.The stock last traded at $6.28 and had previously closed at $4.06.
Separately, ValuEngine lowered Neoleukin Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, December 3rd.
The company has a current ratio of 26.35, a quick ratio of 26.35 and a debt-to-equity ratio of 0.01. The company’s fifty day moving average is $3.61.
Neoleukin Therapeutics (NASDAQ:NLTX) last posted its earnings results on Wednesday, November 13th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.40).
A number of hedge funds have recently added to or reduced their stakes in the stock. Millennium Management LLC purchased a new position in Neoleukin Therapeutics in the third quarter valued at $1,166,000. California Public Employees Retirement System acquired a new position in shares of Neoleukin Therapeutics in the third quarter worth about $162,000. Virtu Financial LLC purchased a new stake in shares of Neoleukin Therapeutics during the 3rd quarter worth about $57,000. Finally, State Street Corp purchased a new stake in shares of Neoleukin Therapeutics during the 3rd quarter worth about $35,000. Institutional investors own 49.15% of the company’s stock.
Neoleukin Therapeutics Company Profile (NASDAQ:NLTX)
Neoleukin Therapeutics, Inc, a biopharmaceutical company, develops immunotherapies using protein design technology. The company's lead product candidate is NL-201, a computationally-designed de novo protein therapeutic for the treatment of IL-2/IL-15 cancer immunotherapy. It also engages in research activities for the treatment of autoimmunity and allergy.
Featured Article: Preferred Stock
Receive News & Ratings for Neoleukin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neoleukin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.